Interim Effectiveness of Updated 2023–2024 (Monovalent XBB.1.5) COVID-19 Vaccines Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalization Among Immunocompetent Adults Aged ≥18 Years — VISION and IVY Networks, September 2023–January 2024

Jennifer DeCuir; Amanda B. Payne; Wesley H. Self; Elizabeth A.K. Rowley; Kristin Dascomb; Malini B. DeSilva; Stephanie A. Irving; Shaun J. Grannis; Toan C. Ong; Nicola P. Klein; Zachary A. Weber; Sarah E. Reese; Sarah W. Ball; Michelle A. Barron; Allison L. Naleway; Brian E. Dixon; Inih Essien; Daniel Bride; Karthik Natarajan; Bruce Fireman; Ami B. Shah; Erica Okwuazi; Ryan Wiegand; Yuwei Zhu; Adam S. Lauring; Emily T. Martin; Manjusha Gaglani; Ithan D. Peltan; Samuel M. Brown; Adit A. Ginde; Nicholas M. Mohr; Kevin W. Gibbs; David N. Hager; Matthew Prekker; Amira Mohamed; Vasisht Srinivasan; Jay S. Steingrub; Akram Khan; Laurence W. Busse; Abhijit Duggal; Jennifer G. Wilson; Steven Y. Chang; Christopher Mallow; Jennie H. Kwon; Matthew C. Exline; Cristie Columbus; Ivana A. Vaughn; Basmah Safdar; Jarrod M. Mosier; Estelle S. Harris; Jonathan D. Casey; James D. Chappell; Carlos G. Grijalva; Sydney A. Swan; Cassandra Johnson; Nathaniel M. Lewis; Sascha Ellington; Katherine Adams; Mark W. Tenforde; Clinton R. Paden; Fatimah S. Dawood; Katherine E. Fleming-Dutra; Diya Surie; Ruth Link-Gelles

doi:10.15585/mmwr.mm7308a5

Interim Effectiveness of Updated 2023–2024 (Monovalent XBB.1.5) COVID-19 Vaccines Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalization Among Immunocompetent Adults Aged ≥18 Years — VISION and IVY Networks, September 2023–January 2024

Jennifer DeCuir, Amanda B. Payne, Wesley H. Self, Elizabeth A.K. Rowley, Kristin Dascomb, Malini B. DeSilva, Stephanie A. Irving, Shaun J. Grannis, Toan C. Ong, Nicola P. Klein, Zachary A. Weber, Sarah E. Reese, Sarah W. Ball, Michelle A. Barron, Allison L. Naleway, Brian E. Dixon, Inih Essien, Daniel Bride, Karthik Natarajan, Bruce FiremanAmi B. Shah, Erica Okwuazi, Ryan Wiegand, Yuwei Zhu, Adam S. Lauring, Emily T. Martin, Manjusha Gaglani, Ithan D. Peltan, Samuel M. Brown, Adit A. Ginde, Nicholas M. Mohr, Kevin W. Gibbs, David N. Hager, Matthew Prekker, Amira Mohamed, Vasisht Srinivasan, Jay S. Steingrub, Akram Khan, Laurence W. Busse, Abhijit Duggal, Jennifer G. Wilson, Steven Y. Chang, Christopher Mallow, Jennie H. Kwon, Matthew C. Exline, Cristie Columbus, Ivana A. Vaughn, Basmah Safdar, Jarrod M. Mosier, Estelle S. Harris, Jonathan D. Casey, James D. Chappell, Carlos G. Grijalva, Sydney A. Swan, Cassandra Johnson, Nathaniel M. Lewis, Sascha Ellington, Katherine Adams, Mark W. Tenforde, Clinton R. Paden, Fatimah S. Dawood, Katherine E. Fleming-Dutra, Diya Surie, Ruth Link-Gelles

Research output: Contribution to journal › Article › peer-review

31 Scopus citations

Abstract

In September 2023, CDC’s Advisory Committee on Immunization Practices recommended updated 2023–2024 (monovalent XBB.1.5) COVID-19 vaccination for all persons aged ≥6 months to prevent COVID-19, including severe disease. However, few estimates of updated vaccine effectiveness (VE) against medically attended illness are available. This analysis evaluated VE of an updated COVID-19 vaccine dose against COVID-19–associated emergency department (ED) or urgent care (UC) encounters and hospitalization among immunocompetent adults aged ≥18 years during September 2023–January 2024 using a test-negative, case-control design with data from two CDC VE networks. VE against COVID-19–associated ED/ UC encounters was 51% (95% CI = 47%–54%) during the first 7–59 days after an updated dose and 39% (95% CI = 33%–45%) during the 60–119 days after an updated dose. VE estimates against COVID-19–associated hospitalization from two CDC VE networks were 52% (95% CI = 47%–57%) and 43% (95% CI = 27%–56%), with a median interval from updated dose of 42 and 47 days, respectively. Updated COVID-19 vaccine provided increased protection against COVID-19–associated ED/UC encounters and hospitalization among immunocompetent adults. These results support CDC recommendations for updated 2023–2024 COVID-19 vaccination. All persons aged ≥6 months should receive updated 2023–2024 COVID-19 vaccine.

Original language	English
Pages (from-to)	180-188
Number of pages	9
Journal	Morbidity and Mortality Weekly Report
Volume	73
Issue number	8
DOIs	https://doi.org/10.15585/mmwr.mm7308a5
State	Published - Feb 29 2024

Access to Document

10.15585/mmwr.mm7308a5

Fingerprint

Dive into the research topics of 'Interim Effectiveness of Updated 2023–2024 (Monovalent XBB.1.5) COVID-19 Vaccines Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalization Among Immunocompetent Adults Aged ≥18 Years — VISION and IVY Networks, September 2023–January 2024'. Together they form a unique fingerprint.

Cite this

DeCuir, J., Payne, A. B., Self, W. H., Rowley, E. A. K., Dascomb, K., DeSilva, M. B., Irving, S. A., Grannis, S. J., Ong, T. C., Klein, N. P., Weber, Z. A., Reese, S. E., Ball, S. W., Barron, M. A., Naleway, A. L., Dixon, B. E., Essien, I., Bride, D., Natarajan, K., ... Link-Gelles, R. (2024). Interim Effectiveness of Updated 2023–2024 (Monovalent XBB.1.5) COVID-19 Vaccines Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalization Among Immunocompetent Adults Aged ≥18 Years — VISION and IVY Networks, September 2023–January 2024. Morbidity and Mortality Weekly Report, 73(8), 180-188. https://doi.org/10.15585/mmwr.mm7308a5

DeCuir, Jennifer ; Payne, Amanda B. ; Self, Wesley H. et al. / Interim Effectiveness of Updated 2023–2024 (Monovalent XBB.1.5) COVID-19 Vaccines Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalization Among Immunocompetent Adults Aged ≥18 Years — VISION and IVY Networks, September 2023–January 2024. In: Morbidity and Mortality Weekly Report. 2024 ; Vol. 73, No. 8. pp. 180-188.

@article{28205bc3ab6c4dc8be18e05c3628ec96,

title = "Interim Effectiveness of Updated 2023–2024 (Monovalent XBB.1.5) COVID-19 Vaccines Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalization Among Immunocompetent Adults Aged ≥18 Years — VISION and IVY Networks, September 2023–January 2024",

abstract = "In September 2023, CDC{\textquoteright}s Advisory Committee on Immunization Practices recommended updated 2023–2024 (monovalent XBB.1.5) COVID-19 vaccination for all persons aged ≥6 months to prevent COVID-19, including severe disease. However, few estimates of updated vaccine effectiveness (VE) against medically attended illness are available. This analysis evaluated VE of an updated COVID-19 vaccine dose against COVID-19–associated emergency department (ED) or urgent care (UC) encounters and hospitalization among immunocompetent adults aged ≥18 years during September 2023–January 2024 using a test-negative, case-control design with data from two CDC VE networks. VE against COVID-19–associated ED/ UC encounters was 51% (95% CI = 47%–54%) during the first 7–59 days after an updated dose and 39% (95% CI = 33%–45%) during the 60–119 days after an updated dose. VE estimates against COVID-19–associated hospitalization from two CDC VE networks were 52% (95% CI = 47%–57%) and 43% (95% CI = 27%–56%), with a median interval from updated dose of 42 and 47 days, respectively. Updated COVID-19 vaccine provided increased protection against COVID-19–associated ED/UC encounters and hospitalization among immunocompetent adults. These results support CDC recommendations for updated 2023–2024 COVID-19 vaccination. All persons aged ≥6 months should receive updated 2023–2024 COVID-19 vaccine.",

author = "Jennifer DeCuir and Payne, {Amanda B.} and Self, {Wesley H.} and Rowley, {Elizabeth A.K.} and Kristin Dascomb and DeSilva, {Malini B.} and Irving, {Stephanie A.} and Grannis, {Shaun J.} and Ong, {Toan C.} and Klein, {Nicola P.} and Weber, {Zachary A.} and Reese, {Sarah E.} and Ball, {Sarah W.} and Barron, {Michelle A.} and Naleway, {Allison L.} and Dixon, {Brian E.} and Inih Essien and Daniel Bride and Karthik Natarajan and Bruce Fireman and Shah, {Ami B.} and Erica Okwuazi and Ryan Wiegand and Yuwei Zhu and Lauring, {Adam S.} and Martin, {Emily T.} and Manjusha Gaglani and Peltan, {Ithan D.} and Brown, {Samuel M.} and Ginde, {Adit A.} and Mohr, {Nicholas M.} and Gibbs, {Kevin W.} and Hager, {David N.} and Matthew Prekker and Amira Mohamed and Vasisht Srinivasan and Steingrub, {Jay S.} and Akram Khan and Busse, {Laurence W.} and Abhijit Duggal and Wilson, {Jennifer G.} and Chang, {Steven Y.} and Christopher Mallow and Kwon, {Jennie H.} and Exline, {Matthew C.} and Cristie Columbus and Vaughn, {Ivana A.} and Basmah Safdar and Mosier, {Jarrod M.} and Harris, {Estelle S.} and Casey, {Jonathan D.} and Chappell, {James D.} and Grijalva, {Carlos G.} and Swan, {Sydney A.} and Cassandra Johnson and Lewis, {Nathaniel M.} and Sascha Ellington and Katherine Adams and Tenforde, {Mark W.} and Paden, {Clinton R.} and Dawood, {Fatimah S.} and Fleming-Dutra, {Katherine E.} and Diya Surie and Ruth Link-Gelles",

year = "2024",

month = feb,

day = "29",

doi = "10.15585/mmwr.mm7308a5",

language = "English",

volume = "73",

pages = "180--188",

journal = "Morbidity and Mortality Weekly Report",

issn = "0149-2195",

number = "8",

}

DeCuir, J, Payne, AB, Self, WH, Rowley, EAK, Dascomb, K, DeSilva, MB, Irving, SA, Grannis, SJ, Ong, TC, Klein, NP, Weber, ZA, Reese, SE, Ball, SW, Barron, MA, Naleway, AL, Dixon, BE, Essien, I, Bride, D, Natarajan, K, Fireman, B, Shah, AB, Okwuazi, E, Wiegand, R, Zhu, Y, Lauring, AS, Martin, ET, Gaglani, M, Peltan, ID, Brown, SM, Ginde, AA, Mohr, NM, Gibbs, KW, Hager, DN, Prekker, M, Mohamed, A, Srinivasan, V, Steingrub, JS, Khan, A, Busse, LW, Duggal, A, Wilson, JG, Chang, SY, Mallow, C, Kwon, JH, Exline, MC, Columbus, C, Vaughn, IA, Safdar, B, Mosier, JM, Harris, ES, Casey, JD, Chappell, JD, Grijalva, CG, Swan, SA, Johnson, C, Lewis, NM, Ellington, S, Adams, K, Tenforde, MW, Paden, CR, Dawood, FS, Fleming-Dutra, KE, Surie, D & Link-Gelles, R 2024, 'Interim Effectiveness of Updated 2023–2024 (Monovalent XBB.1.5) COVID-19 Vaccines Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalization Among Immunocompetent Adults Aged ≥18 Years — VISION and IVY Networks, September 2023–January 2024', Morbidity and Mortality Weekly Report, vol. 73, no. 8, pp. 180-188. https://doi.org/10.15585/mmwr.mm7308a5

Interim Effectiveness of Updated 2023–2024 (Monovalent XBB.1.5) COVID-19 Vaccines Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalization Among Immunocompetent Adults Aged ≥18 Years — VISION and IVY Networks, September 2023–January 2024. / DeCuir, Jennifer; Payne, Amanda B.; Self, Wesley H. et al.
In: Morbidity and Mortality Weekly Report, Vol. 73, No. 8, 29.02.2024, p. 180-188.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Interim Effectiveness of Updated 2023–2024 (Monovalent XBB.1.5) COVID-19 Vaccines Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalization Among Immunocompetent Adults Aged ≥18 Years — VISION and IVY Networks, September 2023–January 2024

AU - DeCuir, Jennifer

AU - Payne, Amanda B.

AU - Self, Wesley H.

AU - Rowley, Elizabeth A.K.

AU - Dascomb, Kristin

AU - DeSilva, Malini B.

AU - Irving, Stephanie A.

AU - Grannis, Shaun J.

AU - Ong, Toan C.

AU - Klein, Nicola P.

AU - Weber, Zachary A.

AU - Reese, Sarah E.

AU - Ball, Sarah W.

AU - Barron, Michelle A.

AU - Naleway, Allison L.

AU - Dixon, Brian E.

AU - Essien, Inih

AU - Bride, Daniel

AU - Natarajan, Karthik

AU - Fireman, Bruce

AU - Shah, Ami B.

AU - Okwuazi, Erica

AU - Wiegand, Ryan

AU - Zhu, Yuwei

AU - Lauring, Adam S.

AU - Martin, Emily T.

AU - Gaglani, Manjusha

AU - Peltan, Ithan D.

AU - Brown, Samuel M.

AU - Ginde, Adit A.

AU - Mohr, Nicholas M.

AU - Gibbs, Kevin W.

AU - Hager, David N.

AU - Prekker, Matthew

AU - Mohamed, Amira

AU - Srinivasan, Vasisht

AU - Steingrub, Jay S.

AU - Khan, Akram

AU - Busse, Laurence W.

AU - Duggal, Abhijit

AU - Wilson, Jennifer G.

AU - Chang, Steven Y.

AU - Mallow, Christopher

AU - Kwon, Jennie H.

AU - Exline, Matthew C.

AU - Columbus, Cristie

AU - Vaughn, Ivana A.

AU - Safdar, Basmah

AU - Mosier, Jarrod M.

AU - Harris, Estelle S.

AU - Casey, Jonathan D.

AU - Chappell, James D.

AU - Grijalva, Carlos G.

AU - Swan, Sydney A.

AU - Johnson, Cassandra

AU - Lewis, Nathaniel M.

AU - Ellington, Sascha

AU - Adams, Katherine

AU - Tenforde, Mark W.

AU - Paden, Clinton R.

AU - Dawood, Fatimah S.

AU - Fleming-Dutra, Katherine E.

AU - Surie, Diya

AU - Link-Gelles, Ruth

PY - 2024/2/29

Y1 - 2024/2/29

N2 - In September 2023, CDC’s Advisory Committee on Immunization Practices recommended updated 2023–2024 (monovalent XBB.1.5) COVID-19 vaccination for all persons aged ≥6 months to prevent COVID-19, including severe disease. However, few estimates of updated vaccine effectiveness (VE) against medically attended illness are available. This analysis evaluated VE of an updated COVID-19 vaccine dose against COVID-19–associated emergency department (ED) or urgent care (UC) encounters and hospitalization among immunocompetent adults aged ≥18 years during September 2023–January 2024 using a test-negative, case-control design with data from two CDC VE networks. VE against COVID-19–associated ED/ UC encounters was 51% (95% CI = 47%–54%) during the first 7–59 days after an updated dose and 39% (95% CI = 33%–45%) during the 60–119 days after an updated dose. VE estimates against COVID-19–associated hospitalization from two CDC VE networks were 52% (95% CI = 47%–57%) and 43% (95% CI = 27%–56%), with a median interval from updated dose of 42 and 47 days, respectively. Updated COVID-19 vaccine provided increased protection against COVID-19–associated ED/UC encounters and hospitalization among immunocompetent adults. These results support CDC recommendations for updated 2023–2024 COVID-19 vaccination. All persons aged ≥6 months should receive updated 2023–2024 COVID-19 vaccine.

AB - In September 2023, CDC’s Advisory Committee on Immunization Practices recommended updated 2023–2024 (monovalent XBB.1.5) COVID-19 vaccination for all persons aged ≥6 months to prevent COVID-19, including severe disease. However, few estimates of updated vaccine effectiveness (VE) against medically attended illness are available. This analysis evaluated VE of an updated COVID-19 vaccine dose against COVID-19–associated emergency department (ED) or urgent care (UC) encounters and hospitalization among immunocompetent adults aged ≥18 years during September 2023–January 2024 using a test-negative, case-control design with data from two CDC VE networks. VE against COVID-19–associated ED/ UC encounters was 51% (95% CI = 47%–54%) during the first 7–59 days after an updated dose and 39% (95% CI = 33%–45%) during the 60–119 days after an updated dose. VE estimates against COVID-19–associated hospitalization from two CDC VE networks were 52% (95% CI = 47%–57%) and 43% (95% CI = 27%–56%), with a median interval from updated dose of 42 and 47 days, respectively. Updated COVID-19 vaccine provided increased protection against COVID-19–associated ED/UC encounters and hospitalization among immunocompetent adults. These results support CDC recommendations for updated 2023–2024 COVID-19 vaccination. All persons aged ≥6 months should receive updated 2023–2024 COVID-19 vaccine.

UR - http://www.scopus.com/inward/record.url?scp=85186288097&partnerID=8YFLogxK

U2 - 10.15585/mmwr.mm7308a5

DO - 10.15585/mmwr.mm7308a5

M3 - Article

C2 - 38421945

AN - SCOPUS:85186288097

SN - 0149-2195

VL - 73

SP - 180

EP - 188

JO - Morbidity and Mortality Weekly Report

JF - Morbidity and Mortality Weekly Report

IS - 8

ER -

DeCuir J, Payne AB, Self WH, Rowley EAK, Dascomb K, DeSilva MB et al. Interim Effectiveness of Updated 2023–2024 (Monovalent XBB.1.5) COVID-19 Vaccines Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalization Among Immunocompetent Adults Aged ≥18 Years — VISION and IVY Networks, September 2023–January 2024. Morbidity and Mortality Weekly Report. 2024 Feb 29;73(8):180-188. doi: 10.15585/mmwr.mm7308a5

Interim Effectiveness of Updated 2023–2024 (Monovalent XBB.1.5) COVID-19 Vaccines Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalization Among Immunocompetent Adults Aged ≥18 Years — VISION and IVY Networks, September 2023–January 2024

Abstract

Access to Document

Other files and links

Fingerprint

Cite this